Exact Sciences Corp. (NASDAQ:EXAS) COO Maneesh Arora sold 562,932 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $17.46, for a total transaction of $9,828,792.72. Following the completion of the transaction, the chief operating officer now owns 1,094,309 shares in the company, valued at $19,106,635.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Exact Sciences Corp. (NASDAQ:EXAS) opened at 17.41 on Wednesday. The stock’s market cap is $1.89 billion. The stock’s 50 day moving average price is $18.01 and its 200-day moving average price is $14.60. Exact Sciences Corp. has a 1-year low of $4.67 and a 1-year high of $22.80.

Exact Sciences Corp. (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, October 26th. The company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.06. Exact Sciences Corp. had a negative return on equity of 55.44% and a negative net margin of 216.45%. The firm had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $25.24 million. During the same period in the previous year, the firm earned ($0.45) EPS. The business’s quarterly revenue was up 122.6% on a year-over-year basis. On average, equities research analysts forecast that Exact Sciences Corp. will post ($1.71) earnings per share for the current year.

Insider Buying and Selling by Quarter for Exact Sciences Corp. (NASDAQ:EXAS)

Several research firms recently weighed in on EXAS. Craig Hallum set a $26.00 price objective on shares of Exact Sciences Corp. and gave the stock a “buy” rating in a research report on Sunday, September 4th. Zacks Investment Research upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Friday, July 29th. Canaccord Genuity restated a “buy” rating and issued a $24.00 price objective on shares of Exact Sciences Corp. in a research report on Friday, October 28th. Benchmark Co. upped their price objective on shares of Exact Sciences Corp. from $14.00 to $17.00 and gave the stock a “hold” rating in a research report on Wednesday, October 26th. Finally, Mizuho upped their price objective on shares of Exact Sciences Corp. from $10.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 27th. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $19.33.

A number of hedge funds have recently modified their holdings of EXAS. State Board of Administration of Florida Retirement System increased its stake in shares of Exact Sciences Corp. by 0.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 77,280 shares of the company’s stock valued at $947,000 after buying an additional 457 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Exact Sciences Corp. by 2.8% in the first quarter. UBS Asset Management Americas Inc. now owns 1,186,519 shares of the company’s stock valued at $7,997,000 after buying an additional 32,579 shares during the period. Strs Ohio increased its stake in shares of Exact Sciences Corp. by 393.6% in the second quarter. Strs Ohio now owns 650,000 shares of the company’s stock valued at $7,962,000 after buying an additional 518,318 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Exact Sciences Corp. by 766.2% in the second quarter. Ameriprise Financial Inc. now owns 232,904 shares of the company’s stock valued at $2,852,000 after buying an additional 206,016 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Exact Sciences Corp. by 7.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 322,874 shares of the company’s stock valued at $3,956,000 after buying an additional 21,193 shares during the period. 87.62% of the stock is currently owned by institutional investors.

About Exact Sciences Corp.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

5 Day Chart for NASDAQ:EXAS

Receive News & Stock Ratings for Exact Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corp. and related stocks with our FREE daily email newsletter.